Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour

@article{Dmont2009HemangiopericytomaAA,
  title={Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour},
  author={Julien D{\^o}mont and Christophe C Massard and Nathalie Lassau and J C Armand and Axel L E Cesne and Jean-Charles Soria},
  journal={Investigational New Drugs},
  year={2009},
  volume={28},
  pages={199-202}
}
Soft tissue sarcomas are a highly heterogeneous group of tumors. Recently, different molecular abnormalities were identified and in some cases corresponding molecular targeted therapies led to significant clinical benefits. Malignant tumors of blood vessels are classified as sarcomas and are uncommon. They encompass angiosarcoma, hemangioendotheliomas, and hemangiopericytomas. The term hemangiopericytoma (HMP) was coined in 1942 by Stout and Murray for soft tissue tumours thought to originate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015

References

Publications referenced by this paper.
Showing 1-5 of 5 references

Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor

MS Park, SR Patel, +6 authors DM Araujo
J Clin Oncol • 2008
View 1 Excerpt

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…